AbbVie Inc. Declares Quarterly Dividend of $1.73 (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) declared a quarterly dividend on Thursday, September 10th. Shareholders of record on Thursday, October 15th will be given a dividend of 1.73 per share on Monday, November 16th. This represents a c) annualized dividend and a yield of 2.7%. The ex-dividend date is Thursday, October 15th.

AbbVie has raised its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 53 years. AbbVie has a dividend payout ratio of 49.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect AbbVie to earn $16.15 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 42.8%.

AbbVie Trading Up 1.6%

Shares of ABBV opened at $255.00 on Friday. The stock has a market cap of $450.52 billion, a P/E ratio of 72.03, a PEG ratio of 1.13 and a beta of 0.29. The company has a 50-day moving average of $254.54 and a two-hundred day moving average of $230.76. AbbVie has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the business earned $2.97 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts forecast that AbbVie will post 14.05 EPS for the current fiscal year.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.